Some notes on a potentially better delivery system than cancer chemo treatment: Poly (D, L-lactic-coglycolic acid) (PLGA)

To repeat: I am not a medic or a scientist. These concepts are far beyond me, but being researched by some smart people around the world. It seems to my untrained eye that many technologies are converging – not least mRNA and its delivery.  

Side note: toxins are required (in the right measure) to make most treatment ingredients work! (h/t Kyle).

A subscriber “Bound” = name translated from the Korean 결박한 provided these comments on Poly (D, L-lactic-coglycolic acid) (PLGA)

“The special processing technology of adjuvants in vaccines is continuously advancing, and with PLGA encapsulation technology, the release rate of antigens and toxins can be controlled within the capsule. The degradation and biodegradation rates of PLGA vary depending on the specified molecular weight, composition, and encapsulation conditions. Generally, PLGA with lower molecular weight degrades and biodegrades more quickly.

Antigens encapsulated in PLGA capsules can typically be released for a few weeks to several months. For example, PLGA with lower molecular weight (10,000-20,000) can provide drug release for a few weeks to a few months, while PLGA with higher molecular weight (50,000-100,000) can sustain release for several months to a few years.

The release rate of the drug can also vary depending on the ratio of lactic acid to glycolic acid in PLGA. Generally, PLGA with a higher glycolic acid ratio degrades faster and leads to faster drug release.

By controlling the molecular weight and composition of PLGA, it may be possible to design capsules that do not cause inflammation in the body and avoid long-lasting COVID symptoms. I believe that having a weakened immune system due to immune suppression can result in extended cold symptoms.”

I looked at this paper for some mre background on the delivery system:

Lipid and PLGA Microparticles for Sustained Delivery of Protein and Peptide Drugs - PubMed (nih.gov)

And Bounds replied with a reference to this paper:

Distinct Proteins in Protein Corona of Nanoparticles Represent a Promising Venue for Endogenous Targeting - Part I: In vitro Release and Intracellular Uptake Perspective - PubMed (nih.gov)

Bound najw these comments:

PLGA-based nanoparticles can encapsulate and protect mRNA, maintaining stability while being capable of transporting it to target tissues or cells. The mRNA acts as a drug within the nanoparticle and is released at the appropriate time to reach the given cells and deliver genes.

Furthermore, the surface of the nanoparticle can be coated with specific ligands or antibodies to allow selective binding to specific cells. This enables mRNA vaccines to be effectively delivered to specific cells for targeted therapy.

Packaging mRNA vaccines in nanoparticle form involves trade secrets such as release kinetics, rate, external control, and gene delivery to specific cells. We should always question and inquire about the potential adverse effects and risks associated with these technologies.

Here’s the conclusion and abstract from the last link.

“Conclusion: Careful engineering of nanocarriers can modulate the recruitment of some proteins suggesting a potential use for achieving endogenous targeting to overcome the current limitations of targeted delivery of chemotherapeutic agents.”

“Introduction: Protein corona (PC) deposition on nanoparticles (NPs) in biological systems contributes to a great extent to NPs' fates; their targeting potential, the interaction with different biological systems and the subsequent functions. PC - when properly tuned - can serve as a potential avenue for optimization of NPs' use in cancer therapy.”

Onwards!

Please subscribe ten bucks a month or annually for 100 bucks. You can also donate via Ko-fi – any amount from three bucks upwards. Ko-fi donations here: https://ko-fi.com/peterhalligan